Scleritis Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Scleritis Market By Type (Anterior Scleritis (Diffuse Scleritis, Nodular Scleritis, and Necrotizing Scleritis), Posterior Scleritis, and Others), Diagnostic Test (Ultrasonography, Complete Blood Count, Biopsy, and Others), Treatment (Medication (Corticosteroid, Nonsteroidal Anti-Inflammatory Drugs, and Immunosuppressive Drugs) and Surgery), End User (Hospitals & Clinics, Diagnostic Centers, and Academic & Research Organizations) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Scleritis Market value is expected to have a CAGR of 5.8% during the forecast period 2022–2028. Scleritis is a medical condition where inflammation occurs in episcleral and scleral tissues with injection in both superficial and deep episcleral vessels. It is reported to cause damage to the cornea, adjacent episclera, and the uvea and thus can be vision-threatening. Scleritis is often associated with an underlying systemic disease in up to 50% of patients and is linked to autoimmune diseases when the body’s immune system attacks and destroys healthy body tissue. For example, rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases. According to a report, out of every 100,000 people, 71 are diagnosed with rheumatoid arthritis each year and around 1.5 million Americans have rheumatoid arthritis. Women are about two to three times more likely to get rheumatoid arthritis than men. The growing geriatric population and increasing per capita income in economic countries, healthcare expenditure, new diagnostic tools, and new therapies invention will drive the overall scleritis market growth. Along with that, the rising prevalence of arthritis, technological advancements in treatment and diagnosis, and the rising incidence of eye diseases will also boost scleritis market growth. According to a report, of 217 061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100 000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Hence, the global scleritis market is expected to maintain its growth during the forecasted years. However, lack of awareness and the absence of targeted treatment and therapies are expected to hinder the scleritis market growth during the forecast period.

Recent Market Developments:

In Oct 2020, U.S. Food and Drug Administration approved Opdivo (nivolumab) and Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

Scleritis Market

MARKET SUMMARY
-
5.8%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.8%
  • Largest Market– Asia Pacific
  • Fastest Growing Market– North America

Scleritis Market

  • The global scleritis market report gives a comprehensive outlook across the globe with particular emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
  • The report on the global scleritis market gives historical, current, and future market sizes on the basis of type, diagnostic test, treatment, end user, and geography.
Key Players
  • Amneal Pharmaceuticals
  • Baxter International
  • Boehringer Ingelheim
  • Mylan Pharmaceuticals
  • Novartis Pharmaceuticals
Scleritis Market Dynamics

The increasing prevalence of scleritis and arthritis is the key driver of the global scleritis market. It is much more observable in aged patients. The growing geriatric population is fueling the market growth in a positive manner. According to WHO, the number and proportion of people aged 60 years and older in the population are increasing. In 2019, the number of people aged 60 years and older was 1 billion. This number will increase to 1.4 billion by 2030 and 2.1 billion by 2050. Hence, the growing geriatric population will drive the global scleritis market in the forecasted years.


North-America Got Significant Share

Scleritis Market

On the basis of regions, the market share is divided into North America, Asia-pacific, Europe, and the Middle East, and the African region. North America holds the major market share in 2021 and is expected to dominate the global scleritis market in the upcoming years due to the advanced healthcare infrastructure, large geriatric population, and the growing prevalence of scleritis within the region. Europe is also expected to grow at a faster pace in the global market due to government initiatives. The Scleritis market in the Asia Pacific is likely to hold a significant revenue share in 2021, and, in the following years, it is predicted to increase rapidly.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The scleritis market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Scleritis Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The scleritis market is projected to expand at a CAGR of 5.8% during the forecast period

Amgen, Amneal Pharmaceuticals, Baxter International, Boehringer Ingelheim, Mylan Pharmaceuticals, Novartis Pharmaceuticals

North America is the fastest-growing region for the scleritis market


Report

Table Of Content

1. Executive Summary
2. Global Scleritis Market Introduction
2.1. Global Scleritis Market – Taxonomy
2.2. Global Scleritis Market –Definitions
2.2.1. By Type
2.2.2. By Diagnostic Test
2.2.3. By Treatment
2.2.4. By End User
2.2.5. By Region
3. Global Scleritis Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Scleritis Market Dynamic Factors – Impact Analysis
3.6. Global Scleritis Market – Competition Landscape
3.7. Epidemiology
4. Global Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028
4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Scleritis Market, By Type, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Anterior Scleritis
5.1.1. Diffuse Scleritis
5.1.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Nodular Scleritis
5.1.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Necrotizing Scleritis
5.1.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.2. Posterior Scleritis
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Scleritis Market, By Diagnostic Test, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1. Ultrasonography
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Complete Blood Count
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Biopsy
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Scleritis Market, By Treatment, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Medication
7.1.1. Corticosteroid
7.1.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.1.3. Market Opportunity Analysis
7.1.2. Nonsteroidal Anti-Inflammatory Drugs
7.1.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.2.3. Market Opportunity Analysis
7.1.3. Immunosuppressive Drugs
7.1.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3.3. Market Opportunity Analysis
7.2. Surgery
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Scleritis Market, By End User, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. Hospitals and Clinics
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Diagnostic Centers
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Academic and Research Institutes
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Scleritis Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Region, 2022-2028
10. North America Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Anterior Scleritis
10.1.1.1. Diffuse Scleritis
10.1.1.2. Nodular Scleritis
10.1.1.3. Necrotizing Scleritis
10.1.2. Posterior Scleritis
10.1.3. Others
10.2. Diagnostic Test Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Ultrasonography
10.2.2. Complete Blood Count
10.2.3. Biopsy
10.2.4. Others
10.3. Treatment Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Medication
10.3.1.1. Corticosteroid
10.3.1.2. Nonsteroidal Anti-Inflammatory Drugs
10.3.1.3. Immunosuppressive Drugs
10.3.2. Surgery
10.4. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospitals and Clinics
10.4.2. Diagnostic Centers
10.4.3. Academic and Reaserach Institutes
10.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2022-2028
10.7. North America Scleritis Market Dynamics – Trends
11. Europe Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Anterior Scleritis
11.1.1.1. Diffuse Scleritis
11.1.1.2. Nodular Scleritis
11.1.1.3. Necrotizing Scleritis
11.1.2. Posterior Scleritis
11.1.3. Others
11.2. Diagnostic Test Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Ultrasonography
11.2.2. Complete Blood Count
11.2.3. Biopsy
11.2.4. Others
11.3. Treatment Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Medication
11.3.1.1. Corticosteroid
11.3.1.2. Nonsteroidal Anti-Inflammatory Drugs
11.3.1.3. Immunosuppressive Drugs
11.3.2. Surgery
11.4. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospitals and Clinics
11.4.2. Diagnostic Centers
11.4.3. Academic and Reaserach Institutes
11.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2022-2028
11.7. Europe Scleritis Market Dynamics – Trends
12. Asia-Pacific Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Anterior Scleritis
12.1.1.1. Diffuse Scleritis
12.1.1.2. Nodular Scleritis
12.1.1.3. Necrotizing Scleritis
12.1.2. Posterior Scleritis
12.1.3. Others
12.2. Diagnostic Test Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Ultrasonography
12.2.2. Complete Blood Count
12.2.3. Biopsy
12.2.4. Others
12.3. Treatment Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Medication
12.3.1.1. Corticosteroid
12.3.1.2. Nonsteroidal Anti-Inflammatory Drugs
12.3.1.3. Immunosuppressive Drugs
12.3.2. Surgery
12.4. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospitals and Clinics
12.4.2. Diagnostic Centers
12.4.3. Academic and Reaserach Institutes
12.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2022-2028
12.7. Asia-Pacific Scleritis Market Dynamics – Trends
13. Latin America Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Anterior Scleritis
13.1.1.1. Diffuse Scleritis
13.1.1.2. Nodular Scleritis
13.1.1.3. Necrotizing Scleritis
13.1.2. Posterior Scleritis
13.1.3. Others
13.2. Diagnostic Test Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Ultrasonography
13.2.2. Complete Blood Count
13.2.3. Biopsy
13.2.4. Others
13.3. Treatment Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Medication
13.3.1.1. Corticosteroid
13.3.1.2. Nonsteroidal Anti-Inflammatory Drugs
13.3.1.3. Immunosuppressive Drugs
13.3.2. Surgery
13.4. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospitals and Clinics
13.4.2. Diagnostic Centers
13.4.3. Academic and Reaserach Institutes
13.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2022-2028
13.7. Latin America Scleritis Market Dynamics – Trends
14. Middle East and Africa Scleritis Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
14.1. Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Anterior Scleritis
14.1.1.1. Diffuse Scleritis
14.1.1.2. Nodular Scleritis
14.1.1.3. Necrotizing Scleritis
14.1.2. Posterior Scleritis
14.1.3. Others
14.2. Diagnostic Test Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Ultrasonography
14.2.2. Complete Blood Count
14.2.3. Biopsy
14.2.4. Others
14.3. Treatment Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Medication
14.3.1.1. Corticosteroid
14.3.1.2. Nonsteroidal Anti-Inflammatory Drugs
14.3.1.3. Immunosuppressive Drugs
14.3.2. Surgery
14.4. End User Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospitals and Clinics
14.4.2. Diagnostic Centers
14.4.3. Academic and Reaserach Institutes
14.5. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. MEA Scleritis Market – Opportunity Analysis Index, By Type, By Diagnostic Test, By Treatment, By End User, and Country, 2022-2028
14.7. MEA Scleritis Market Dynamics – Trends
15. Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Key Types, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Amgen
15.2.2. Amneal Pharmaceuticals
15.2.3. Baxter International
15.2.4. Boehringer Ingelheim
15.2.5. Mylan Pharmaceuticals
15.2.6. Novartis Pharmaceuticals
15.2.7. Perrigo Company
15.2.8. Fresenius Kabi
15.2.9. Jubilant Cadista Pharmaceuticals
15.2.10. Roxane Laboratories
15.2.11. Sandoz Inc
15.2.12. Shanghai Henlius Biotech
15.2.13. Teva Pharmaceuticals
16. Research Methodology
17. Key Assumptions and Acronyms

Report

Company Profile

  • Amgen
  • Amneal Pharmaceuticals
  • Baxter International
  • Boehringer Ingelheim
  • Mylan Pharmaceuticals
  • Novartis Pharmaceuticals
  • Perrigo Company
  • Fresenius Kabi
  • Jubilant Cadista Pharmaceuticals
  • Roxane Laboratories
  • Sandoz Inc
  • Shanghai Henlius Biotech
  • Teva Pharmaceuticals

Description

Scleritis Market value is expected to have a CAGR of 5.8% during the forecast period 2022–2028. Scleritis is a medical condition where inflammation occurs in episcleral and scleral tissues with injection in both superficial and deep episcleral vessels. It is reported to cause damage to the cornea, adjacent episclera, and the uvea and thus can be vision-threatening. Scleritis is often associated with an underlying systemic disease in up to 50% of patients and is linked to autoimmune diseases when the body’s immune system attacks and destroys healthy body tissue. For example, rheumatoid arthritis and systemic lupus erythematosus are autoimmune diseases. According to a report, out of every 100,000 people, 71 are diagnosed with rheumatoid arthritis each year and around 1.5 million Americans have rheumatoid arthritis. Women are about two to three times more likely to get rheumatoid arthritis than men. The growing geriatric population and increasing per capita income in economic countries, healthcare expenditure, new diagnostic tools, and new therapies invention will drive the overall scleritis market growth. Along with that, the rising prevalence of arthritis, technological advancements in treatment and diagnosis, and the rising incidence of eye diseases will also boost scleritis market growth. According to a report, of 217 061 eligible patients, 17 incident scleritis cases and 93 incident episcleritis cases were confirmed. The overall incidence rates of scleritis and episcleritis were 4.1 (95% CI: 2.6-6.6) and 21.7 (95% CI: 17.7-26.5) cases per 100 000 person-years, respectively. Women were overrepresented among scleritis patients (P = .049). Hence, the global scleritis market is expected to maintain its growth during the forecasted years. However, lack of awareness and the absence of targeted treatment and therapies are expected to hinder the scleritis market growth during the forecast period.

Recent Market Developments:

In Oct 2020, U.S. Food and Drug Administration approved Opdivo (nivolumab) and Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX